An official website of the United States government
Home
Name
Vyloy
Alternate Names
Zolbetuximab
Zolbertuximab-clzb
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Cytolytic antibody
NSC Number
None
Primary Site
Stomach, GE junction
Histology
None
Remarks
October 18, 2024 FDA approved zolbetuximab-clzb (Vyloy), a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2 positive, as determined by an FDA-approved test.
Coding
This drug should be coded
